ketanserin has been researched along with Hakim Syndrome in 1 studies
Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.
ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Olsen, KS | 1 |
| Albeck, M | 1 |
| Agerlin, N | 1 |
| Schmidt, JF | 1 |
1 other study available for ketanserin and Hakim Syndrome
| Article | Year |
|---|---|
The effect of ketanserin on ICP and CBF in patients with normal-pressure hydrocephalus.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Cerebrovascular Circulation; Female; Humans; H | 1996 |